Sobi™ Satellite Symposium

Agenda

Welcome | Sophie Georgin-Lavialle (Chair)
Putting on your goggles - An introduction to VEXAS | Sophie Georgin-Lavialle
External presentation - Dermatologic features of VEXAS | Thibault Mahevas
Under the skin - Rheumatologic features of VEXAS | Sara Bindoli
Deep, into the marrow - Hematologic features of VEXAS | Lachelle D. Weeks
Panel discussion and Q&A | All Faculty

Download Slides (2.2 MB)

Publication

EULAR •
14 June, 2025 •
•

Variations in Chronic Refractory Gout Management between Rheumatologists and Nephrologists

Kenneth Saag , Nana Kragh, Amod Athavale, Bhavisha Desai, Amal Gulaid, Abiola Oladapo, Brittany Smith, Hyon Choi

Available materials

Poster

Publication

EULAR •
14 June, 2025 •
•

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

David B. Beck, Mael Heiblig, Sinisa Savic, Marcela A. Ferrada, Arsene Mekinian, Onima Chowdhury, Danielle Hammond, Lachelle D. Weeks, Carmelo Gurnari, Yohei Kirino , Sophie Georgin-Lavialle, Sarah A. Buckley, Bryan G. Harder, Sandra Goble, Matthew J. Koster

Available materials

Poster

Publication

EULAR •
14 June, 2025 •
•

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)

Kevin Byram, Herman Mann, Danielle Hammond, Sinisa Savic, Yohei Kirino , Carmelo Gurnari, Mael Heiblig, Thibault Comont, Arsene Mekinian, Mrinal Patnaik, Lachelle D. Weeks, Gary Ho, Onima Chowdhury, Adam Al-Hakim, Scott Goldberg, Marcela A. Ferrada, Sophie Georgin-Lavialle, Peter Grayson, Emma M. Groarke, Bhavisha Patel, Megan Sullivan, Sarah A. Buckley, Bryan G. Harder, Sandra Goble, Matthew J. Koster, David B. Beck

Putting on your VEXAS goggles: Seeing what’s in plain sight

Variations in Chronic Refractory Gout Management between Rheumatologists and Nephrologists

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)

Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research

Management of Uncontrolled Gout Among Nephrology Professionals: Findings from a Medical Chart Audit

Nanoencapsulated Sirolimus Plus Pegadricase (NASP) Reduces Gout Clinical Manifestations in Patients with Uncontrolled Gout (UG) and Stage 3 CKD

Effect of Nanoencapsulated Sirolimus plus Pegadricase (NASP) on Kidney Outcomes: Results from the Phase 3 DISSOLVE Studies

Patient, Caregiver, and Physician Perspectives on the Burden of Disease Chronic Refractory Gout and its Treatment: Concept Elicitation

Putting on your VEXAS goggles: Seeing what’s in plain sight​

Putting on your VEXAS goggles: Seeing what’s in plain sight